<DOC>
	<DOC>NCT00215150</DOC>
	<brief_summary>The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment alone</brief_summary>
	<brief_title>Geodon for the Treatment of Refractory Social Anxiety Disorder</brief_title>
	<detailed_description>This is a two-phase study consisting of 8 weeks of open label treatment with sertraline (50-200 mg/day) in patients with SAD and in those who fail to demonstrate symptom remission on sertraline alone, 8 weeks of randomized, double-blind, placebo-controlled augmentation with ziprasidone.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<criteria>adults 1865 years of age primary diagnosis of SAD, using Diagnostic Standard Manual(DSMIV) criteria minimum Clinical Global Impression of Severity (CGIS) score of 4 at baseline minimum Brief Social Phobia Scale(BSPS) score of 20 at baseline written informed consent negative serum pregnancy test for women of childbearing potential normal EKG current DSMIV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, mental retardation or other pervasive developmental disorder, or cognitive disorder due to a general medical condition any current primary anxiety disorder other than SAD current primary depression history of substance abuse or dependence within the last 3 months suicide risk or serious suicide attempt within the last year clinically significant medical condition or laboratory or EKG abnormality women of childbearing potential who are unwilling to practice an acceptable method of contraception patients needing concurrent use of psychotropic medications history of hypersensitivity to sertraline or ziprasidone recent (less than 2 months) initiation of psychotherapy for SAD history of failure to respond to augmentation with an adequate trial of an atypical antipsychotic patients who are currently taking any of the following medications: Erythromycin, Biaxin, Avelox, Zithromax, Amantadine, Levaquin, Tamoxifen, Tegretol, Nizoral, and Levitra</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>anxiety disorder</keyword>
	<keyword>SAD</keyword>
	<keyword>ziprasidone</keyword>
	<keyword>sertraline</keyword>
	<keyword>antidepressant</keyword>
	<keyword>antipsychotic</keyword>
</DOC>